COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($) |
1 Months Ended | 3 Months Ended | 12 Months Ended | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 13, 2018 |
Dec. 10, 2015 |
Mar. 28, 2019 |
Feb. 14, 2019 |
Jul. 28, 2016 |
Mar. 31, 2019 |
Dec. 31, 2018 |
Dec. 31, 2016 |
Dec. 31, 2017 |
Nov. 20, 2015 |
Oct. 19, 2015 |
|
| Lease expiration date | Jun. 30, 2019 | ||||||||||
| Intangible assets , carrying value | $ 0 | ||||||||||
| Grant awarded from NIDA | $ 5,674,268 | ||||||||||
| Grants receivable from NIDA in year one | 2,842,430 | ||||||||||
| Grants receivable from NIDA in year two | 2,831,838 | ||||||||||
| Grants received from NIDA | 224,059 | ||||||||||
| Revenue recognized related to NIDA grant | 224,059 | ||||||||||
| Deffered revenue - grant | 66,000 | ||||||||||
| Operating leases [Member] | |||||||||||
| Lease expiration date | Sep. 30, 2024 | ||||||||||
| Rent expense escalation, description | The extended lease has escalating payments from $5,522 per month to $6,552 per month | ||||||||||
| Extension of lease term, description | The Company extended the term of its lease for an additional 63 months beginning July 1, 2019 (at expiry of the original lease) | ||||||||||
| Alpine Creek Capital Partners LLC [Member] | |||||||||||
| Total royalty payable | $ 405,000 | ||||||||||
| Deposit amount | $ 55,000 | ||||||||||
| Cancellation of secured promissory note | $ 55,000 | ||||||||||
| Payables to the Company | 295,000 | ||||||||||
| Payables to Alpine Creek | $ 1,215,000 | ||||||||||
| Payable commitment description | In the event that the Company has not paid Alpine Creek $1,215,000 within 24 months of the Effective Date, then the Company shall continue to pay Alpine Creek fifty percent (50%) for each Treatment following the Effective Date until the Company has paid Alpine Creek an aggregate of $1,620,000, with the exception of treatments conducted in certain territories | ||||||||||
| Payable per treatment sold | $ 100 | ||||||||||
| Profit holding percentage | 50.00% | ||||||||||
| Therakine, Ltd. [Member] | |||||||||||
| License cost | $ 2,750,000 | ||||||||||
| Aggregate purchase price | $ 250,000 | $ 250,000 | $ 250,000 | ||||||||
| Escrow deposit | 75,000 | $ 75,000 | |||||||||
| Impairment loss | $ 250,000 | ||||||||||
| Therakine, Ltd. [Member] | Maximum [Member] | |||||||||||
| Sales of products | 12.00% | ||||||||||
| Therakine, Ltd. [Member] | Minimum [Member] | |||||||||||
| Sales of products | 5.00% | ||||||||||
| Lucido Subscription and Royalty Agreement [Member] | |||||||||||
| Subscription and royalty agreement description | Pursuant to the Lucido Subscription and Royalty Agreement: (i) Mr. Lucido purchased shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), in the aggregate amount of $3,000,000 at a purchase price of $15.00 per share (the “Purchase Price”), for a total of 200,000 shares of Common Stock; and (ii) the Company shall pay Lucido (a) a total of $37.50 from the gross revenue derived from each of its weight loss treatments sold in the United States starting on the first (1st) day that the first unit of the treatment is sold (the “Initial Sales Date”) and ending on the third (3rd) anniversary of the Initial Sales Date; and (b) a total of $25.00 from the gross revenue derived from each of its weight loss treatments sold in the United States starting on the day following the third (3rd) anniversary of the Initial Sales Date and ending on the fifteenth (15th) anniversary of the Initial Sales Date (the “Royalty”) | ||||||||||
| Description for the use of proceeds under agreement | The Company will use no less than 65% of the proceeds of the aggregate Purchase Price of the Lucido Subscription and Royalty Agreement exclusively to develop, launch and expand the Company’s weight loss program (the “Business”) including sales and marketing activities directly related to the Business, and shall be free to use up to 35% of the aggregate Purchase Price of the Lucido Subscription and Royalty Agreement for general working capital and administration, and for further product development. With the prior written consent of Mr. Lucido, the Company may use more than 35% of the aggregate Purchase Price for general working capital and administration, and for further product development | ||||||||||
| Employment Agreements [Member] | Tom Welch [Member] | |||||||||||
| Annual salary | $ 150,000 | ||||||||||
| Monthly car allowance and reimbursements for health and medical insurance | $ 500 | ||||||||||
| Stock option period | 10 years | ||||||||||
| Stock options to purchase common shares | 75,000 | ||||||||||
| Exercise price | $ 14.00 | ||||||||||
| Employment Agreements [Member] | Ms. Lourdes Felix [Member] | |||||||||||
| Annual salary | $ 175,000 | ||||||||||
| Monthly car allowance and reimbursements for health and medical insurance | $ 500 | ||||||||||
| Stock option period | 10 years | ||||||||||
| Stock options to purchase common shares | 75,000 | ||||||||||
| Exercise price | $ 14.00 | ||||||||||
| Employment Agreements [Member] | Brady Granier [Member] | |||||||||||
| Annual salary | $ 175,000 | ||||||||||
| Monthly car allowance and reimbursements for health and medical insurance | $ 500 | ||||||||||
| Stock option period | 10 years | ||||||||||
| Stock options to purchase common shares | 75,000 | ||||||||||
| Exercise price | $ 14.00 | ||||||||||